|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2521-2526.
Prepublished online as a Blood First Edition Paper on September 27, 2007; DOI 10.1182/blood-2007-08-104984.
 Previous Article | Next Article 
Submitted August 2, 2007
Accepted September 22, 2007
Recent major improvement in long-term survival
of younger patients with multiple myeloma
Hermann Brenner*, Adam Gondos, and Dianne Pulte
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
Weill Cornell Medical Center, New York, NY, United States
* Corresponding author; email: h.brenner{at}dkfz-heidelberg.de.
In the past, most patients with multiple myeloma (MM) died within 5-10 years following diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem cell transplant, thalidomide, lenalidomide, and bortezomib. We estimated trends in age specific 5- and 10-year relative survival of MM patients in the United States from 1990-1992 to 2002-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Techniques of period analysis were employed to disclose most recent developments. Overall, 5-year relative survival increased from 28.8% to 34.7% (p<0.0001), and 10-year relative survival increased from 11.1% to 17.4% (p<0.0001) between 1990-92 and 2002-04. Much stronger increases were seen in age group <50, leading to 5- and 10-year relative survival of 56.7% and 41.3% in 2002-04, and in age group 50-59, leading to 5- and 10-year relative survival of 48.2% and 28.6% in 2002-2004. By contrast, only moderate improvement was seen in age group 60-69, and essentially no improvement was achieved among older patients. Our period analysis discloses a major increase in long-term survival of younger patients with MM in recent years which most likely reflects the impact of recent advances in therapy and their dissemination in clinical practice.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
The road to cure in multiple myeloma
- Irene M. Ghobrial and Kenneth C. Anderson
Blood 2008 111: 2503.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al.
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network
Ann. Onc.,
May 22, 2009;
(2009)
mdn796v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Kristinsson, A. R. Derolf, G. Edgren, P. W. Dickman, and M. Bjorkholm
Socioeconomic Differences in Patient Survival Are Increasing for Acute Myeloid Leukemia and Multiple Myeloma in Sweden
J. Clin. Oncol.,
April 20, 2009;
27(12):
2073 - 2080.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Blade and L. Rosinol
Changing paradigms in the treatment of multiple myeloma
Haematologica,
February 1, 2009;
94(2):
163 - 166.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Brenner, A. Gondos, and D. Pulte
Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010
Haematologica,
February 1, 2009;
94(2):
270 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ludwig, B. G. M. Durie, V. Bolejack, I. Turesson, R. A. Kyle, J. Blade, R. Fonseca, M. Dimopoulos, K. Shimizu, J. San Miguel, et al.
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
Blood,
April 15, 2008;
111(8):
4039 - 4047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
